Bladder Cancer

Papers
(The median citation count of Bladder Cancer is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Single-cell RNA sequencing and spatial transcriptome analysis in bladder cancer: Current status and future perspectives12
Advancing Clinical Trial Design for Non-Muscle Invasive Bladder Cancer11
Predicting Recurrence and Progression in Patients with Non-Muscle-Invasive Bladder Cancer: Systematic Review on the Performance of Risk Stratification Models10
Urologists and Advanced Practice Providers Evaluating Hematuria9
No Association Between BCG Instillations and COVID-19 Incidence in a Dutch Non-Muscle Invasive Bladder Cancer Cohort9
Clinical Trials Corner Issue 9(2)8
Intravesical instillation of chemotherapy before surgery for upper tract urothelial cancer8
Comparison of Robotic vs Open Cystectomy: A Systematic Review7
Standard vs extended lymphadenectomy for muscle invasive bladder cancer7
Expression of PD-1 and PD-L1 in BCG-treated NMIBC6
Orthotopic bladder cancer preclinical models: Comprehensive review and technique optimization6
Reduced Dose Intravesical Bacillus Calmette-Guérin: Why It Might Not Matter6
Evaluation of the Effects of Opium on the Expression of SOX2 and OCT4 in Wistar Rat Bladder6
Management of bladder cancer in kidney transplant recipients: A narrative review6
Loss of Cxcr2 in Myeloid Cells Promotes Tumour Progression and T Cell Infiltration in Invasive Bladder Cancer5
Non-Muscle Invasive Bladder Cancer: Many More Patients Die With It Than Of It5
Organoid models in bladder cancer: From bench to bedside?5
A New Standard of Care for Bladder Cancer5
Clinical Trials Corner Issue 10(2)5
Efficacy of Surgery on the Primary Tumour in Patients with Metastatic Bladder Cancer: A Comprehensive Review5
Systemic induction therapy in patients with locally advanced or node-positive urothelial carcinoma: Evaluating treatment outcomes4
Mechanism of Sex Differences in Bladder Cancer: Evident and Elusive Sex-biasing Factors4
Molecular Basis of Tumorigenesis of Bladder Cancer and Emerging Concepts in Developing Therapeutic Targets3
The role of blue light cystoscopy and additional operative evaluations during first surveillance after induction therapy for high-risk NMIBC3
Commentary on Novitas LCD3
Clinical Trials Corner Issue 8(2)3
Challenging Cases in Urothelial Cancer: Case 273
Y Chromosome Loss and Bladder Cancer3
Immune Checkpoint Inhibitors in Metastatic Bladder and Other Solid Malignancies: How Long is Enough?3
Platinum-based chemotherapy rechallenge or enfortumab vedotin after maintenance avelumab or pembrolizumab for locally advanced or metastatic urothelial carcinoma3
Adjuvant Chemotherapy Plus Radiotherapy versus Chemotherapy Alone for Locally Advanced Bladder Cancer after Radical Cystectomy3
Challenging Cases in Urothelial Cancer: Case 263
Challenging Cases in Urothelial Cancer: Case 333
Does Blue Light Cystoscopy Reduce Recurrences of Non-Muscle Invasive Bladder Cancer?3
Patterns of Smoking Cessation Strategies and Perception of E-cigarette Harm Among Bladder Cancer Survivors3
Editorial Concerning “The Association Between Diabetes Medication Use and Tumour Characteristics at Diagnosis in Patients with Urothelial Carcinoma: A Retrospective Registry-Based Study”2
Novel Delivery Mechanisms for Existing Systemic Agents and Emerging Therapies in Bladder Cancer2
MHC I Expression Predicts Response to Checkpoint Inhibitors in Metastatic Urothelial Carcinoma but Lacks Prognostic Value in Localized Disease2
Electromotive Drug Administration Chemotherapy with Mitomycin C Versus Bacillus Calmette-Guerin for the Treatment of Non-Muscle Invasive Bladder Cancer2
Switch Maintenance Therapy for Metastatic Urothelial Carcinoma2
NK Cell-Targeted Immunotherapies in Bladder Cancer: Beyond Checkpoint Inhibitors2
Open vs Robotic Surgery2
Longitudinal Analysis of Bladder Cancer-Specific Mortality Trends in the United States2
Efficacy of Antibody Drug Conjugates Alone and in Combination with other Agents in Metastatic Urothelial Carcinoma: A Scoping Review2
Higher resilience in radical cystectomy patients is associated with improved health related quality of life post-operatively1
Challenging Cases in Urothelial Cancer: Case 30: Rare Complication of BCG1
What is a Bladder Cancer Molecular Subtype?1
Neoadjuvant Intravesical Chemotherapy for Non-muscle Invasive Bladder Cancer1
Comparative Analysis of Very Reduced vs Full Dose BCG Treatment for High-Risk Non-Muscle Invasive Bladder Cancer: A Contemporary Experience from Chile1
SH3BP5-AS1/IGF2BP2/VDAC2 Axis Promotes the Apoptosis and Ferroptosis of Bladder Cancer Cells1
BCG in Immunocompromised Patients: Is it effective? Is it safe?1
Implementing a New Standard of Care1
Factors Influencing Patient Decision-Making in the Treatment of Muscle-Invasive Bladder Cancer1
Impact of Adjuvant Gemcitabine Containing Chemotherapy Following Radical Nephroureterectomy for Patients with Upper Tract Urothelial Carcinoma: Results from a Propensity-Score Matched Cohort Study1
Is There A Benefit of Restaging Transurethral Resection of Bladder Tumor Prior to Radical Cystectomy With or Without Neoadjuvant Chemotherapy?1
Multi-Center Assessment of Lymph-Node Density and Nodal-Stage to Predict Disease-Specific Survival in Patients with Bladder Cancer Treated by Radical Cystectomy1
Neoadjuvant Cisplatin, Gemcitabine, and Docetaxel in Sarcomatoid Bladder Cancer: Clinical Activity and Whole Transcriptome Analysis1
Advancements in systemic therapy for muscle-invasive bladder cancer: A systematic review from the beginning to the latest updates1
Urothelial carcinoma and the potential clinical application of urinary extracellular vesicles: Current Status and prospects1
Impact of neighborhood deprivation on bladder cancer outcomes: A regional analysis1
BCG therapy for bladder cancer: Exploring patient experiences and concerns through artificial intelligence-based social media analysis1
A Multicenter Study of 2-year Outcomes Following Hyperthermia Therapy with Mitomycin C in Treating Non-Muscle Invasive Bladder Cancer: HIVEC-E1
An Association Study of Germline Variants in Bladder Cancer-Related Genes with the Prognosis of Non-Muscle Invasive Bladder Cancer1
When a ‘routine’ TURBT is not routine: Lessons from SEER-medicare1
Serum metabolomic analysis identified serum biomarkers predicting tumour recurrence after Bacillus Calmette–Guérin therapy in patients with non-muscle invasive bladder cancer1
Head-to-Head Comparison between High-Resolution Microultrasound Imaging and Multiparametric MRI in Detecting and Local Staging of Bladder Cancer: The BUS-MISS Protocol1
Physical Activity and Health-related Quality of Life from Diagnosis to One Year After Radical Cystectomy in Patients with Bladder Cancer: A Longitudinal Cohort Study1
Urethral Melanoma – Clinical, Pathological and Molecular Characteristics1
Clinical Trials Corner Issue 9(4)1
0.25052404403687